KISQALI was demonstrated to improve or maintain quality of life in all three clinical trials^1–4

KISQALI + endocrine therapy can help give patients quality time, improving or maintaining measures such as pain, fatigue and gastrointestinal symptoms.^1–4

AI, aromatase inhibitor; EOT, end of treatment; QoL, quality of life; TTD, time to deterioration.

*KISQALI is not recommended to be used in combination with tamoxifen.⁵

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.⁵

References

1. Beck JT, et al. P6-18-14. Presented at 2018 San Antonio Breast Cancer Symposium, 4–8 December 2018, San Antonio, Texas, USA.
2. Harbeck N, et al. Abstract 2910. Presented at ESMO 2018 Congress, 19–23 October 2018, Munich, Germany.
3. Verma S, et al. Breast Cancer Res Treat 2018;170(3):535–545.
4. Fasching PA, et al. Presented at European Society for Medical Oncology Congress, 19–23 October 2018, Munich, Germany.
5. KISQALI^® (ribociclib) Summary of Product Characteristics.